Who Paid My Doc
Kathryn Hassell
Hematology Aurora, CO Medical Doctor
NPI 1629168307 CMS profile 380806
12605 E 16Th Ave, Room L28-3203, Aurora, CO 80045
General payments
$6,474
Research payments
$7,295
Ownership & investment interest
$0
Research they led as principal investigator
$280,169
Through program year 2024, Kathryn Hassell of Aurora, CO is reported in the CMS Open Payments database as having received $6,474 across 21 general payments and $7,295 in research payments paid to them. Separately, studies naming them as principal investigator received $280,169 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 63rd percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $95 | 1 | |
| 2023 | General | $3,502 | 4 | |
| 2022 | General | $187 | 3 | |
| 2021 | Research | $1,400 | 1 | |
| 2020 | Research | $4,140 | 2 | |
| 2019 | General | $2,689 | 13 | |
| 2019 | Research | $1,755 | 14 |
Beside peers
- Kathryn Hassell
- Hematology median
- Middle half of Hematology
- National median
In program year 2025, general payments to Kathryn Hassell were reported at $0. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.
Show as a table
| Year | Kathryn Hassell | Hematology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,689 | $1,012 | $122–$9,834 | $163 |
| 2020 | $0 | $1,475 | $115–$9,198 | $114 |
| 2021 | $0 | $1,470 | $125–$7,444 | $132 |
| 2022 | $187 | $1,371 | $139–$8,471 | $149 |
| 2023 | $3,502 | $1,295 | $147–$11,010 | $160 |
| 2024 | $95 | $1,286 | $146–$9,230 | $164 |
| 2025 | $0 | $1,155 | $135–$8,023 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 9 billing codesPaid by Medicare
$6,169
Medicare patients
86
Services billed
161
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 63% | |
| Arthritis | 53% | |
| Depression | 34% | |
| Chronic kidney disease | 29% | |
| Diabetes | 24% | |
| Heart failure | 20% | |
| Ischemic heart disease | 20% | |
| COPD | 15% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
38 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology in Colorado
Related records
Hematology in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Hematology
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.